Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascletis PharmaFRA:2VJ +6.04%42 Days Payable is 228.13 as of Dec. 2025, which is 350% above its 10-year median of 50.70. GuruFocus rates FRA:2VJ with a GF Score™ of 42/100 and a GF Value™ of €0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 702 Biotechnology companies, Ascletis Pharma ranks better than 50.14% on this metric.
The historical rank and industry rank for Ascletis Pharma's Days Payable or its related term are showing as below:
FRA:2VJ'
s Days Payable Range Over the Past 10 Years
Min: 9.46 Med: 50.7 Max: 408.63
Current: 113.76
During the past 10 years, Ascletis Pharma's highest Days Payable was 408.63. The lowest was 9.46. And the median was 50.70.
FRA:2VJ's Days Payable is ranked better than 50.14% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs FRA:2VJ: 113.76
Ascletis Pharma's Days Payable
increased
from Dec. 2024 (79.84) to Dec. 2025 (228.13).
It may suggest that Ascletis Pharmadelayed paying its suppliers.
Ascletis Pharma Days Payable Related Terms
Ascletis Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2VJ vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Ascletis Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ascletis Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (FRA:2VJ) has a Days Payable of 228.13 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ascletis Pharma and its competitors. This is 350% above median its historical median of 50.70. Over the past decade, Ascletis Pharma's Days Payable has ranged from 9.46 to 408.63. According to the industry distribution chart, Ascletis Pharma ranks #350 out of 702 companies in the Biotechnology industry, placing it in the top 49.9%.
Is Ascletis Pharma's Days Payable too high?
Ascletis Pharma's current Days Payable of 228.13 is 350% above median its 10-year median of 50.70. Over the past 10 years, this metric has ranged from a low of 9.46 to a high of 408.63. The Biotechnology industry median Days Payable is 113.10. Ascletis Pharma's value of 228.13 is 101.7% above this industry median. Based on the distribution chart, Ascletis Pharma ranks #350 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascletis Pharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #350 out of 702 companies for Days Payable. This puts Ascletis Pharma in the upper half of its industry. The industry median Days Payable is 113.10. Ascletis Pharma's value of 228.13 is 101.7% above this benchmark. Historically, Ascletis Pharma's own Days Payable has ranged from 9.46 to 408.63 over the past decade. While the company's 10-year median is 50.70 vs. the industry median of 113.10, Ascletis Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Days Payable of 228.13 is 101.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ascletis Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Days Payable is 228.13, which is 350% above median its own 10-year median of 50.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (FRA:2VJ) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.02, compared to a current price of €0.97 — trading 4725% above its estimated fair value. The current Days Payable is 228.13, which is 350% above median its 10-year median of 50.70 and 101.7% above the Biotechnology industry median of 113.10. Ascletis Pharma's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ascletis Pharma (FRA:2VJ), the current Days Payable is 228.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (FRA:2VJ) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of €0.97 is trading 4725% above its estimated GF Value™ of €0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for FRA:2VJ:
Days Payable: 228.13 (350% above median its 10-year median of 50.70)
GF Value™: €0.02 vs. price of €0.97 (4725% above fair value)
Industry Position: 101.7% above the Biotechnology median (#350 of 702)
No single metric tells the full story. See the FRA:2VJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
42GF Score
Get the complete analysis for FRA:2VJ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2VJ has been successfully added to your 
